Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Public ClinicalTrials.gov record NCT00423254. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Multicenter, Open Label, Clinical Trial of Immune Response, Safety and Tolerability of DNA Vector pPRA-PSM With Synthetic Peptides E-PRA and E-PSM in Subjects With Advance Solid Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.
Study identification
- NCT ID
- NCT00423254
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 12 participants
Conditions and interventions
Conditions
- Ovarian
- Melanoma
- Renal
- Prostate
- Colorectal
- Endometrial Carcinoma
- Cervical Carcinoma
- Testicular Cancer
- Thyroid Cancer
- Small Cell Lung Carcinoma
- Mesothelioma
- Breast Carcinoma
- Esophageal Carcinoma
- Gastric Cancer
- Pancreatic Carcinoma
- Neuroendocrine Cancer
- Liver Cancer
- Gallbladder Cancer
- Biliary Tract Cancer
- Anal Carcinoma
- Bone Sarcomas
- Soft Tissue Sarcomas
- Carcinoma of Unknown Origin, Primary
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2007
- Primary completion
- Aug 31, 2009
- Completion
- Oct 31, 2009
- Last update posted
- Aug 2, 2010
2007 – 2009
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center | Tuscon | Arizona | 85724-5024 | — |
| Lombardi Comprehensive Cancer Center at Georgetown | Washington D.C. | District of Columbia | 20057 | — |
| H Lee Moffitt Cancer Center University of So Florida | Tampa | Florida | 33612 | — |
| Nevada Cancer Institute | Sparks | Nevada | 89431 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00423254, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2010 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00423254 live on ClinicalTrials.gov.